Navigation Links
Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100

MILPITAS, Calif., Jan. 8, 2016 /PRNewswire/ -- Protagonist Therapeutics, Inc., a company developing novel, orally-stable peptide therapeutics for gastrointestinal (GI) diseases, today announced that the company has initiated treatment of subjects with its lead drug candidate, PTG-100, in a Phase 1 clinical study. Protagonist is developing PTG-100, an orally-stable alpha-4-beta-7 integrin-specific peptide antagonist, as a potential treatment for patients with inflammatory bowel disease (IBD).

"IBD is a chronic inflammatory disease of the gastro-intestinal tract where there is significant need for improved targeted therapies," said Richard Shames, M.D., Chief Medical Officer at Protagonist. "PTG-100 is the only oral alpha-4-beta-7 specific antagonist currently in development, a target that is clinically validated for IBD by the approval of injectable antibody drugs."

"The initiation of the first human study of PTG-100 is an important milestone for Protagonist, marking our evolution from a research-focused company to one engaged in the clinical development of its own products," said Dinesh Patel, Ph.D., Protagonist President and Chief Executive Officer. "PTG-100 is the first of several orally stable peptides in the Protagonist pipeline. We look forward to applying the lessons we learn from this compound's early development to our other programs."

The Phase 1 study, which is being conducted in Australia, is a randomized, double-blind, placebo-controlled, dose-escalation trial in 70 normal healthy volunteers. The first part of the study consists of single-ascending doses of PTG-100 in 40 volunteers. The second part of the study will involve the administration of PTG-100 over 14 consecutive days in 30 additional volunteers. Primary endpoints for the study are safety and tolerability of PTG-100. Secondary endpoints are the identification of the maximally tolerated dose and evaluation of pharmacokinetic and pharmacodynamic parameters.

About Protagonist Therapeutics

Protagonist Therapeutics is a U.S.-incorporated biotechnology company engaged in the discovery and development of orally stable peptides as targeted therapies initially for inflammatory bowel disease (IBD) and other gastrointestinal diseases and disorders. The company has an innovative and proprietary technology platform that enables it to develop potent and orally stable peptides for protein-protein interaction (PPI) targets that have been approached largely by injectable antibodies. Oral peptides may lead to a preferred choice for patients, physicians, and payers by virtue of their better convenience and potentially enhanced safety and efficacy in comparison to other therapeutic options. In addition to PTG-100, Protagonist has several other assets in different stages of research and pre-clinical development.

Protagonist is headquartered in Milpitas, California USA with its pre-clinical and clinical staff in California, and discovery operations both in California and in Brisbane, Queensland, Australia. For further information, please visit

Logo -


SOURCE Protagonist Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Protagonist Therapeutics Names David Liu Chief Scientific Officer
2. Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
3. Protagonist Therapeutics Closes 2nd Tranche of $18 Million Series B for Advancing Development Candidate to Clinical Trials in 2015
4. Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer
5. Protagonist Therapeutics Receives SBIR Funding for Oral IL-23 Receptor Antagonists for Treatment of Inflammatory Bowel Diseases
6. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
7. Novelos Therapeutics Provides Product Pipeline Update
8. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
9. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
11. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
Post Your Comments:
(Date:9/17/2019)... ... 17, 2019 , ... AssuriCare LLC , an innovation ... , the first and most compliant online management platform developed for registries ... and caregiver relationship management. RegistryConnect is available only to home care companies operating ...
(Date:9/17/2019)... ... 17, 2019 , ... Today, in partnership with Lehman College, ... consent with student and faculty from The City University of New York (CUNY). ... MPH; Elise Schuster, MPH; Raffaele M. Bernardo, DO, FACP, AAHIVS and Stuart Chen-Hayes, ...
(Date:9/17/2019)... OBISPO, Calif. (PRWEB) , ... September 17, 2019 , ... Summer is a time for ... it is good for our teeth and gums. Dr. Douglas Ng, family dentist in ... Warm weather is the time for ice cream, and popsicles and ice-filled cold drinks to ...
Breaking Medicine Technology:
(Date:9/17/2019)... ... September 17, 2019 , ... Milwaukee-area dealership Hall Cars has hosted an annual event each fall ... event, entitled “Drive Out Cancer,” entails that for every vehicle purchased from Sept. 17 to ... event lasts for 50 days, it has also been referred to as, “50 for 50.” ...
(Date:9/17/2019)... Calif. (PRWEB) , ... September 17, 2019 , ... ... CE Mark for Europe and the 21st Century Cures Act in the US, ... surgery, radiology, and pain management. Using images from existing MRI equipment to ...
(Date:9/17/2019)... TN (PRWEB) , ... September 17, 2019 , ... ... Periodontics and Dental Implants welcome patients with missing teeth in Chattanooga, TN for ... completed by a periodontist in as little as one day, providing a permanent ...
(Date:9/17/2019)... (PRWEB) , ... September 17, 2019 , ... Lubin ... reception fundraiser. Gather for GRIN2B will be held at Found Kitchen and ... , Proceeds will help fund research on GRIN2B-Related Neurodevelopmental Disorder, a rare condition that ...
(Date:9/17/2019)... ... September 17, 2019 , ... Genomenon today ... the goal of providing resources to assist researchers and encourage pharmaceutical companies to ... causing abnormal iron deposits in the brain. , BPAN Warriors is an ...
Breaking Medicine News(10 mins):